B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.